Free light chains: Eclectic multipurpose biomarker

Journal of Immunological Methods

Volumn 451, Issue , 2017, Pages 11-19

  Basile, Umberto ^a   Gulli, Francesca ^a   Gragnani, Laura ^b   Napodano, Cecilia ^a   Pocino, Krizia ^a   Rapaccini, Gian Ludovico ^a   Mussap, Michele ^c   Zignego, Anna Linda ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Autoimmune diseases; Free light chains; Immediate hypersensitivity; Multiple sclerosis; Rituximab; Viral infections

Indexed keywords

IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; POLYCLONAL ANTIBODY; RITUXIMAB; BIOLOGICAL MARKER; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOLOGIC FACTOR;

AUTOIMMUNE DISEASE; CHRONIC KIDNEY FAILURE; DISEASE MARKER; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE RESPONSE; MULTIPLE SCLEROSIS; NONHUMAN; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; VIRUS INFECTION; ANIMAL; CHEMISTRY; DRUG MONITORING; IMMUNOLOGY; METABOLISM; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; AUTOIMMUNE DISEASES; BIOMARKERS; DRUG MONITORING; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN CONFORMATION; RENAL INSUFFICIENCY, CHRONIC; RITUXIMAB; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS DISEASES;

EID: 85029749957     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2017.09.005     Document Type: Review

References (106)

1. Aggarwal, R., Sequeira, W., Kokebie, R., Mikolaitis, R.A., Fogg, L., Finnegan, A. et al., Serum free light chains as biomarker for systemic lupus erythematus disease activity. Arthritis Care Res. 63 (2011), 891–898.
2. Anandram, S., Assi, L.K., Lovatt, T., Parkes, J., Taylor, J., MacWhannell, A. et al., Elevated, combined serum free light chain levels and increased mortality: a 5-year follow-up, UK study. J. Clin. Pathol. 65 (2012), 1036–1042.
3. Assi, L.K., McIntyre, N., Fraser, S., Harris, S., Hutchison, C.A., McIntyre, C.W. et al., The association between polyclonal combined serum free light chain concentration and mortality in individuals with early chronic kidney disease. PLoS One, 10(7), 2015, e0129980.
4. Basile, U., Gragnani, L., Piluso, A., Gulli, F., Urraro, T., Dell'Abate, M.T. et al., Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment. Liver Int. 35:9 (2015), 2100–2107 (Sep).
5. Basnayake, K., Stringer, S.J., Hutchison, C.A., Cockwell, P., The biology of immunoglobulin free light chains and kidney injury. Kidney Int. 79 (2011), 1289–1301.
6. Bence, Jones H., Papers on chemical pathology: prefaced by the Gulstonian lectures, read at the Royal College of Physicians, 1846. Lancet 50 (1847), 88–92.
7. Berggård, I., Peterson, P.A., Polymeric forms of free normal kappa and lambda chains of human immunoglobulin. J. Biol. Chem. 244 (1969), 4299–4307.
8. Bibas, M., Trotta, M.P., Cozzi-Lepri, A., Lorenzini, P., Pinnetti, C., Rizzardini, G. et al., Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. Am. J. Hematol. 87 (2012), 749–753.
9. Boivin, D., Provençal, M., Gendron, S., Ratel, D., Demeule, M., Gingras, D. et al., Purification and characterization of a stimulator of plasmin generation from the antiangiogenic agent Neovastat: identification as immunoglobulin kappa light chain. Arch. Biochem. Biophys. 431 (2004), 197–206.
10. Braber, S., Thio, M., Blokhuis, B.R., Henricks, P.A., Koelink, P.J., Groot Kormelink, T. et al., An association between neutrophils and immunoglobulin free light chains in the pathogenesis of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 185 (2012), 817–824.
11. Bradwell, A.R., Carr-Smith, H.D., Mead, G.P., Tang, L.X., Showell, P.J., Drayson, M.T. et al., Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin. Chem. 47 (2001), 673–680.
12. Bramlage, C.P., Froelich, B., Wallbach, M., Minguet, J., Grupp, C., Deutsch, C. et al., The significance and predictive value of free light chains in the urine of patients with chronic inflammatory rheumatic disease. Clin. Rheumatol. 35:12 (2016), 2939–2946.
13. Briand, P.Y., Decaux, O., Caillon, H., Grosbois, B., Le Treut, A., Guenet, L., Analytical performance of the serum free light chain assay. Clin. Chem. Lab. Med. 48 (2010), 73–79.
14. Brouwer, J., Otting-van de Ruit, M., Buskung-van der Lely, H., Estimation of free light chains of immunoglobulins by enzyme immunoassay. Clin. Chim. Acta 150 (1985), 267–274.
15. Burmeister, A., Assi, L.K., Ferro, C.J., Hughes, R.G., Barnett, A.H., Bellary, S. et al., The relationship between high-sensitivity CRP and polyclonal free light chains as markers of inflammation in chronic disease. Int. J. Lab. Hematol. 36 (2014), 415–424.
16. Campbell, J.P., Heaney, J.L., Shemar, M., Baldwin, D., Griffin, A.E., Oldridge, E. et al., Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum κ and λ immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool. Clin. Chem. Lab. Med., 2016 (Epub ahead of print 2016 Aug 9) http://dx.doi.org/10.1515/cclm-2016-0194.
17. Charafeddine, K.M., Jabbour, M.N., Kadi, R.H., Daher, R.T., Extended use of serum free light chain as a biomarker in lymphoproliferative disorders: a comprehensive review. Am. J. Clin. Pathol. 137 (2012), 890–897.
18. Chice, L., Cournac, J.M., Mancini, J., Bardin, N., Thomas, G., Jean, R. et al., Normalization of serum free light chains in patients with systemic lupus erythematosus upon rituximab treatment and correlation with biological disease activity. Clin. Rheumatol. 30 (2011), 685–689.
19. Cigliana, G., Gulli, F., Napodano, C., Pocino, K., De Santis, E., Colacicco, L. et al., Serum free light chain quantitative assays: dilemma of a biomarker. J. Clin. Lab. Anal., 2017, 10.1002/jcla.22243.
20. Cooper, A., Bluestone, R., Free immunoglobulin light chains in connective tissue diseases. Ann. Rheum. Dis. 27 (1968), 537–543.
21. Desjardins, L., Liabeuf, S., Lenglet, A., Lemke, H.D., Vanholder, R., Choukroun, G. et al., European Uremic Toxin (EUTox) work group. Association between free light chain levels, and disease progression and mortality in chronic kidney disease. Toxins (Basel). 5 (2013), 2058–2073.
22. Dispenzieri, A., Kyle, R., Merlini, G., Miguel, J.S., Ludwig, H., Hajek, R. et al., International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23:2 (2009), 215–224 (Feb).
23. Draborg, A.H., Lydolph, M.C., Westergaard, M., Olesen Larsen, S., Nielsen, C.T., Duus, K. et al., Elevated concentrations of serum immunoglobulin free light chains in systemic lupus erythematosus patients in relation to disease activity, inflammatory status, B cell activity and Epstein-Barr virus antibodies. PLoS One, 11(1), 2016, e0148151 (Jan 25).
24. Duranti, F., Pieri, M., Centonze, D., Buttari, F., Bernardini, S., Dessi, M., Determination of kFLC and K index in cerebrospinal fluid: a valid alternative to assess intrathecal immunoglobulin synthesis. J. Neuroimmunol. 263 (2013), 116–120.
25. Edelman, G.M., Gaily, J.A., The nature of Bence Jones proteins: chemical similarities to polypeptide chains of myeloma globulins and normal gamma-globulins. J. Exp. Med. 116 (1962), 202–227.
26. Edmundson, A.B., Ely, K.R., Binding of N-formylated chemotactic peptides in crystals of the mcg light chain dimer: similarities with neutrophil receptors. Mol. Immunol. 22 (1985), 463–475.
27. Edmundson, A.B., Ely, K.R., Herron, J.N., Cheson, B.D., The binding of opioid peptides to the mcg light chain dimer: flexible keys and adjustable locks. Mol. Immunol. 24 (1987), 915–935.
28. Ehrlich, P., On immunity with special reference to cell life. Proc. Roy. Soc. London 66 (1900), 424–448.
29. Eickhoff, K., Heipertz, R., Wikström, J., Determination of k/l immunoglobulin light chain ratios in CSF from patients with multiple sclerosis and other neurological diseases. Acta Neurol. Scand. 57 (1978), 385–395.
30. Engels, E.A., Pfeiffer, R.M., Landgren, O., Moore, R.D., Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era. J. Acquir. Immune Defic. Syndr. 54 (2010), 78–84.
31. Epstein, W.V., Tan, M., Increase of L-chain proteins in the sera of patients with systemic lupus erythematosus and the synovial fluids of patients with peripheral rheumatoid arthritis. Arthritis Rheum. 9 (1966), 713–719.
32. Fischer, C., Arneth, B., Koehler, J., Lotz, J., Lackner, K.J., Kappa free light chains in cerebrospinal fluid as markers of intrathecal immunoglobulin synthesis. Clin. Chem. 50 (2004), 1809–1813.
33. Foy, S.P., Matsuuchi, L., Association of B lymphocyte antigen receptor polypeptides with multiple chaperone proteins. Immunol. Lett. 78 (2001), 149–160.
34. Freedman, M.S., Thomson, E.J., Deisenhammer, F., Giovannoni, G., Grimsley, G., Keir, G. et al., Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis. A consensus statement. Arch. Neurol. 62 (2005), 865–870.
35. Gottenberg, J.E., Aucouturier, F., Goetz, J., Sordet, C., Jahn, I., Busson, M. et al., Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjögren syndrome. Ann. Rheum. Dis. 66 (2007), 23–27.
36. Gottenberg, J.E., Seror, R., Miceli-Richard, C., Benessiano, J., Devauchelle-Pensec, V., Dieude, P. et al., Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at the enrollment in the prospective ASSESS cohort. PLoS One, 8(5), 2013, e59868.
37. Gragnani, L., Fognani, E., Piluso, A., Boldrini, B., Urraro, T., Fabbrizzi, A. et al., Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology 61:4 (2015), 1145–1153.
38. Graziani, M.S., Merlini, G., Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions. Expert. Rev. Mol. Diagn. 14 (2014), 55–66.
39. Groot Kormelink, T., Pardo, A., Knipping, K., Buendía-Roldán, I., García-de-Alba, C., Blokhuis, B.R. et al., Immunoglobulin free light chains are increased in hypersensitivity pneumonitis and idiopathic pulmonary fibrosis. PLoS One, 6, 2011, e25392.
40. Groot Kormelink, T., Powe, D.G., Kuijpers, S.A., Abudukelimu, A., Fens, M.H., Pieters, E.H. et al., Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation. Oncotarget 5:10 (2014), 3159–3167.
41. Hassan-Smith, G., Durant, L., Tsentemeidou, A., Assi, L.K., Faint, J.M., Kalra, S. et al., High sensitivity and specificity of elevated cerebrospinal fluid kappa free light chains in suspected multiple sclerosis. J. Neuroimmunol. 276:1–2 (2014), 175–179 (Nov 15).
42. Haynes, R., Hutchison, C.A., Emberson, J., Dasgupta, T., Wheeler, D.C., Townend, J.N. et al., Serum free light chains and the risk of ESRD and death in CKD. Clin. J. Am. Soc. Nephrol. 6 (2011), 2829–2837.
43. Hopper, J.E., Sequeira, W., Martellotto, J., Papagiannes, E., Perna, L., Skosey, J.L., Clinical relapse in systemic lupus erythematosus: correlation with antecedent elevation of urinary free light chain immunoglobulin. J. Clin. Immunol. 9 (1989), 338–350.
44. Hopper, J.E., Golbus, J., Meyer, C., Ferrer, G.A., Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig. J. Clin. Immunol. 20 (2000), 123–137.
45. van Houwelingen, A.H., Kaczynska, K., Kraneveld, A.D., Kool, M., Nijkamp, F.P., Redegeld, F.A., Topical application of F991, an immunoglobulin free light chain antagonist, prevents development of contact sensitivity in mice. Clin. Exp. Allergy 37 (2007), 270–275.
46. Hutchison, C.A., Landgren, O., Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation. Clin. Chem. 57 (2011), 1387–1389.
47. Hutchison, C.A., Burmeister, A., Harding, S.J., Basnayake, K., Church, H., Jesky, M.D. et al., Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney disease. Mayo Clin. Proc. 89 (2014), 615–622.
48. Jacobs, J.F., Tate, J.R., Merlini, G., Is accuracy of serum free light chain measurement achievable?. Clin. Chem. Lab. Med. 54:6 (2016), 1021–1030.
49. Johansson, S.G., Bieber, T., Dahl, R., Friedmann, P.S., Lanier, B.Q., Lockey, R.F. et al., Revised nomenclature for allergy for global use: report of the nomenclature review Committee of the World Allergy Organization, October 2003. J. Allergy Clin. Immunol. 113 (2004), 832–836.
50. Jokiranta, T.S., Solomon, A., Pangburn, M.K., Zipfel, P.F., Meri, S., Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J. Immunol. 163 (1999), 4590–4596.
51. Jolly, M., Francis, S., Aggarwal, R., Mikolaitis, R., Niewold, T., Chubinskaya, S. et al., Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus. Lupus 23:9 (2014), 881–888 (Aug).
52. Kaplan, B., Golderman, S., Yahalom, G., Yeskaraev, R., Ziv, T., Aizenbud, B.M. et al., Free light chain monomer-dimer patterns in the diagnosis of multiple sclerosis. J. Immunol. Methods 390:1–2 (2013), 74–80 (Apr 30).
53. Kayserova, J., Capkova, S., Skalicka, A., Vernerova, E., Polouckova, A., Malinova, V. et al., Serum immunoglobulin free light chains in severe forms of atopic dermatitis. Scand. J. Immunol. 71 (2010), 312–316.
54. Kormelink, T.G., Tekstra, J., Thurlings, R.M., Boumans, M.H., Vos, K., Tak, P.P. et al., Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity. Ann. Rheum. Dis. 69 (2010), 2137–2144.
55. Krakauer, M., Schaldemose Nielsen, H., Jensen, J., Sellebjerg, F., Intrathecal synthesis of free immunoglobulin light chains in multiple sclerosis. Acta Neurol. Scand. 98 (1998), 161–165.
56. Kraneveld, A.D., van der Kleij, H.P., Kool, M., van Houwelingen, A.H., Weitenberg, A.C., Redegeld, F.A. et al., Key role for mast cells in nonatopic asthma. J. Immunol. 169 (2002), 2044–2053.
57. Kraneveld, A.D., Kool, M., van Houwelingen, A.H., Roholl, P., Solomon, A., Postma, D.S. et al., Elicitation of allergic asthma by immunoglobulin free light chains. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 1578–1583.
58. Lamers, K.J., de Jong, J.G., Jongen, P.J., Kock-Jansen, M.J., Teunesen, M.A., Prudon-Rosmulder, E.M., Cerebrospinal fluid free kappa light chains versus IgG findings in neurological disorders: qualitative and quantitative measurements. J. Neuroimmunol. 62 (1995), 19–25.
59. Landgren, O., Goedert, J.J., Rabkin, C.S., Wilson, W.H., Dunleavy, K., Kyle, R.A. et al., Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J. Clin. Oncol. 28 (2010), 773–779.
60. Levinson, S.S., Studies of Bence Jones proteins by immunonephelometry. Ann. Clin. Lab. Sci. 22 (1992), 100–109.
61. Liu, Y., New insights into epithelial-mesenchymal transition in kidney fibrosis. J. Am. Soc. Nephrol. 21 (2010), 212–222.
62. Maack, T., Johnson, V., Kau, S.T., Figueiredo, J., Sigulem, D., Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int. 16 (1979), 251–270.
63. Mancini, G., Carbonara, A.O., Heremans, J.F., Immunological quantitation of antigens by single radial immunodiffusion. Immunochemistry 2 (1965), 235–254.
64. Matsumori, A., Shimada, M., Jie, X., Higuchi, H., Groot Kormelink, T., Redegeld, F.A., Effects of free immunoglobulin light chains on viral myocarditis. Circ. Res. 106 (2010), 1533–1540.
65. Mazilu, D., Opriş, D., Gainaru, C., Iliuta, M., Apetrei, N., Luca, G. et al., Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment. Biomed. Res. Int., 2014, 2014, 702701.
66. Meixlsperger, S., Köhler, F., Wossning, T., Reppel, M., Müschen, M., Jumaa, H., Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. Immunity 26 (2007), 323–333.
67. Monti, G., Pioltelli, P., Saccardo, F., Campanini, M., Candela, M., Cavallero, G. et al., Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch. Intern. Med. 165 (2005), 101–105.
68. Oliveira, I.S., Cabral, M.S., Jesus, L.S., Paraná, R., Atta, A.M., Sousa Atta, M.L., Serum levels of immunoglobulin free light chains in patients with chronic hepatitis C presenting cryoglobulinemia. Braz. J. Infect. Dis. 18:6 (2014), 638–642 (Nov-Dec).
69. Paroli, M., Iannucci, G., Accapezzato, D., Hepatitis C virus infection and autoimmune diseases. Int. J. Gen. Med. 5 (2012), 903–907.
70. Paul, S., Li, L., Kalaga, R., Wilkins-Stevens, P., Stevens, F.J., Solomon, A., Natural catalytic antibodies: peptide-hydrolyzing activities of Bence Jones proteins and VL fragment. J. Biol. Chem. 270 (1995), 15257–15261.
71. Porter, R.R., Structural studies of immunoglobulins. Science 180:4087 (1973), 713–716.
72. Powe, D.G., Groot Kormelink, T., Sisson, M., Blokhuis, B.J., Kramer, M.F., Jones, N.S. et al., Evidence for the involvement of free light chain immunoglobulins in allergic and nonallergic rhinitis. J. Allergy Clin. Immunol. 125 (2010), 139–145.
73. Presslauer, S., Milosavljevic, D., Brücke, T., Bayer, P., Hübl, W., Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. J. Neurol. 255 (2008), 1508–1514.
74. Presslauer, S., Milosavljevic, D., Huebl, W., Aboulenein-Djamshidian, F., Krugluger, W., Deisenhammer, F. et al., Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: a multicenter study. Mult. Scler. 22:4 (2016), 502–510 (Apr).
75. Pretorius, C.J., Klingberg, S., Tate, J., Wilgen, U., Ungerer, J.P., Evaluation of the N latex FLC free light chain assay on the Siemens BN analyser: precision, agreement, linearity and variation between reagent lots. Ann. Clin. Biochem. 49 (2012), 450–455.
76. Putnam, F.W., Hardy, S., Proteins in multiple myeloma. III. Origin of Bence Jones protein. J. Biol. Chem. 212 (1955), 361–369.
77. Rajkumar, S.V., Dimopoulos, M.A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.V. et al., International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15 (2014), 538–548.
78. Ramsden, D.B., Multiple sclerosis: assay of free immunoglobulin light chains. Ann. Clin. Biochem. 54:1 (2017), 5–13.
79. Redegeld, F.A., Nijkamp, F.P., Immunoglobulin free light chains and mast cells: pivotal role in T-cell-mediated immune reactions?. Trends Immunol. 24 (2003), 181–185.
80. Redegeld, F.A., van der Heijden, M.W., Kool, M., Heijdra, B.M., Garssen, J., Kraneveld, A.D. et al., Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat. Med. 8 (2002), 694–701.
81. Ritchie, J., Assi, L.K., Burmeister, A., Hoefield, R., Cockwell, P., Kalra, P.A., Association of Serum Ig Free Light Chains with mortality and ESRD among patients with nondialysis-dependent CKD. Clin. J. Am. Soc. Nephrol. 10 (2015), 740–749.
82. Robinson, E.L., Gowland, E., Ward, I.D., Scarffe, J.H., Radioimmunoassay of free light chains of immunoglobulins in urine. Clin. Chem. 28 (1982), 2254–2258.
83. Rudick, R.A., Peter, D.R., Bidlack, J.M., Knutson, D.W., Multiple sclerosis: free light chains in cerebrospinal fluid. Neurology 35 (1985), 1443–1449.
84. Rudick, R.A., French, C.A., Breton, D., Williams, G.W., Relative diagnostic value of cerebrospinal fluid kappa chains in MS: comparison with other immunoglobulin tests. Neurology 39 (1989), 964–968.
85. Sansonno, D., Russi, S., Conteduca, V., Sansonno, L., B-cell frequency in HCV-related mixed cryoglobulinemia. Hepatology, 58(1), 2012, 448 (Oct 30).
86. Schouten, B., van Esch, B.C., van Thuijl, A.O., Blokhuis, B.R., Groot Kormelink, T., Hofman, G.A. et al., Contribution of IgE and immunoglobulin free light chain in the allergic reaction to cow's milk proteins. J. Allergy Clin. Immunol. 125 (2010), 1308–1314.
87. Sengul, S., Zwizinski, C., Simon, E.E., Kapasi, A., Singhal, P.C., Batuman, V., Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells. Kidney Int. 62 (2002), 1977–1988.
88. SøIling, K., Free light chains of immunoglobulins in normal serum and urine determined by radioimmunoassay. Scand. J. Clin. Lab. Invest. 35 (1975), 407–412.
89. Sølling, K., Polymeric forms of free light chains in serum from normal individuals and from patients with renal diseases. Scand. J. Clin. Lab. Invest. 36 (1976), 447–452.
90. Sølling, J., Sølling, K., Free light chains of immunoglobulins in amyloidosis. Acta Med Scand 206 (1979), 283–287.
91. Sølling, K., Sølling, J., Rømer, F.K., Free light chains of immunoglobulins in serum from patients with rheumatoid arthritis, sarcoidosis, chronic infections and pulmonary cancer. Acta Med. Scand. 209 (1981), 473–477.
92. Solomon, A., Bence Jones proteins and light chains of immunoglobulins (first of two parts). N. Engl. J. Med. 294 (1976), 17–23.
93. Sun, M., Gao, Q.S., Li, L., Paul, S., Proteolytic activity of an antibody light chain. J. Immunol. 153 (1994), 5121–5126.
94. Te Velthuis, H., Knop, I., Stam, P., van den Broek, M., Bos, H.K., Hol, S., N latex FLC – new monoclonal high performance assays for the determination of free light chain kappa and lambda. Clin. Chem. Lab. Med. 49 (2011), 1323–1332.
95. Teng, J., Russell, W.J., Gu, X., Cardelli, J., Jones, M.L., Herrera, G.A., Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab. Investig. 84 (2004), 440–451.
96. Terrier, B., Sene, D., Saadoun, D., Ghillani-Dalbin, P., Thibault, V., Delluc, A. et al., Serum free light chain assessment in hepatitis C virus-related lymphoproliferative disorders. Ann. Rheum. Dis. 68 (2009), 89–93.
97. Thiagarajan, P., Dannenbring, R., Matsuura, K., Tramontano, A., Gololobov, G., Paul, S., Monoclonal antibody light chain with prothrombinase activity. Biochemistry 39 (2000), 6459–6465.
98. Thio, M., Blokhuis, B.R., Nijkamp, F.P., Redegeld, F.A., Free immunoglobulin light chains: a novel target in the therapy of inflammatory diseases. Trends Pharmacol. Sci. 29 (2008), 170–174.
99. Tillyer, C.R., Iqbal, J., Raymond, J., Gore, M., Mc Ilwain, T.J., Immunoturbidimetric assay for estimating free light chains of immunoglobulins in urine and serum. J. Clin. Pathol. 44 (1991), 466–471.
100. Tiselius, A., Kabat, E.A., An electrophoretic study of immune sera and purified antibody preparations. J. Exp. Med. 69 (1939), 119–131.
101. Tonelli, M., Sacks, F., Pfeffer, M., Jhangri, G.S., Curhan, G., Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 68 (2005), 237–245.
102. Van den Beucken, T., Van Neer, N., Sablon, E., Desmet, J., Celis, L., Hoogenboom, H.R. et al., Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains. J. Mol. Biol. 310 (2001), 591–601.
103. Van der Heijden, M., Kraneveld, A., Redegeld, F., Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. Eur. J. Pharmacol. 533 (2006), 319–326.
104. VanDuijn, M.M., Jacobs, J.F., Wevers, R.A., Engelke, U.F., Joosten, I., Luider, T.M., Quantitative measurement of immunoglobulins and free light chains using mass spectrometry. Anal. Chem. 87:16 (2015), 8268–8274 (Aug 18).
105. Ye, Y., Li, S.L., Xie, M., Jiang, P., Liu, K.G., Li, Y.J., Judging disease activity in rheumatoid arthritis by serum free kappa and lambda light chain levels. Kaohsiung J. Med. Sci. 29:10 (2013), 547–553 (Oct).
106. Zignego, A.L., Giannini, C., Ferri, C., Hepatitis C virus-related lymphoproliferative disorders: an overview. World J. Gastroenterol. 13 (2007), 2467–2478.